Movfor: Advanced Antiviral Treatment for Influenza and Beyond
| Product dosage: 200mg | |||
|---|---|---|---|
| Package (num) | Per cap | Price | Buy |
| 40 | $7.35 | $294.18 (0%) | 🛒 Add to cart |
| 80 | $6.20 | $588.36 $495.99 (16%) | 🛒 Add to cart |
| 120 | $5.81 | $882.54 $697.80 (21%) | 🛒 Add to cart |
| 160 | $5.62 | $1176.72 $899.61 (24%) | 🛒 Add to cart |
| 200 | $5.51
Best per cap | $1470.90 $1101.41 (25%) | 🛒 Add to cart |
Synonyms | |||
Movfor (favipiravir) is a broad-spectrum antiviral medication designed to target and inhibit RNA-dependent RNA polymerase, a critical enzyme for viral replication. Developed for the treatment of influenza, its mechanism of action allows for potential application against a range of RNA viruses, offering a versatile therapeutic option. With a well-established pharmacokinetic profile, Movfor ensures rapid absorption and distribution, making it a frontline choice in managing viral infections where timely intervention is crucial. Its efficacy is supported by clinical data demonstrating significant reductions in viral load and symptom duration.
Features
- Active ingredient: Favipiravir 200 mg per tablet
- Mechanism: Selective inhibitor of RNA-dependent RNA polymerase
- Formulation: Film-coated tablets for oral administration
- Packaging: Blister packs of 10 tablets, with 50 tablets per carton
- Shelf life: 36 months from date of manufacture
- Storage: Room temperature (15–30°C), protected from light and moisture
Benefits
- Rapid onset of action, with detectable plasma concentrations within hours of administration
- Significantly reduces duration of influenza symptoms, including fever and respiratory distress
- Low potential for development of viral resistance due to its unique mechanism
- Well-tolerated profile with a favorable safety record in clinical use
- Oral administration allows for outpatient treatment, reducing hospitalization needs
- Broad-spectrum activity provides utility in off-label scenarios for emerging RNA viruses
Common use
Movfor is primarily indicated for the treatment of novel or re-emerging influenza virus infections in adults, particularly in cases where other antiviral medications are ineffective or contraindicated. It is prescribed both for treatment and, in specific public health contexts, as prophylactic measure during outbreaks. Off-label use has been documented in cases of other RNA viral infections, though such application requires careful risk-benefit assessment by treating physicians.
Dosage and direction
Loading dose: 1600 mg twice daily on the first day (total 3200 mg)
Maintenance dose: 600 mg twice daily from day 2 through day 5 (total 6000 mg over treatment course)
Administration should occur with or without food, though taking with meals may reduce potential gastrointestinal discomfort. Tablets must be swallowed whole with water; crushing or chewing is not advised. Dosage adjustments may be necessary in patients with renal or hepatic impairment—consult prescribing information for specific guidance.
Precautions
- Use with caution in patients with history of gout or hyperuricemia, as favipiravir may increase serum uric acid levels
- Not recommended during pregnancy (Category D) due to potential embryotoxic effects observed in animal studies
- Breastfeeding should be discontinued during treatment and for 7 days after final dose
- Monitor liver function tests periodically in patients with pre-existing hepatic conditions
- Use with caution in elderly patients (>65 years), considering potential for reduced renal clearance
Contraindications
- Hypersensitivity to favipiravir or any excipients in the formulation
- Severe renal impairment (CrCl <30 mL/min)
- Pregnancy and women of childbearing potential not using contraception
- Pediatric patients under 18 years (safety and efficacy not established)
Possible side effects
Most side effects are mild to moderate and self-limiting. Commonly reported include:
- Elevated serum uric acid (14–28% of patients)
- Diarrhea (4–7%)
- Transaminase elevation (3–5%)
- Nausea (2–4%)
- Headache (1–3%)
Rare but serious adverse effects (<1%) may include:
- Acute kidney injury
- Severe hepatotoxicity
- Stevens-Johnson syndrome (case reports)
Drug interaction
- Probenecid: May decrease favipiravir clearance, increasing exposure
- Xanthine oxidase inhibitors: Potential reduced efficacy due to mechanism conflict
- Pyrazinamide: Additive effect on uric acid elevation
- Other nephrotoxic agents: Increased risk of renal adverse events
- No clinically significant interactions with CYP450 substrates observed
Missed dose
If a dose is missed within 4 hours of the scheduled time, administer immediately. If more than 4 hours have passed, skip the missed dose and resume the regular dosing schedule. Do not double the dose to make up for missed administration.
Overdose
No specific antidote exists. Cases of overdose (up to 12,000 mg single dose reported) manifested primarily as gastrointestinal distress and transient uric acid elevation. Management should include symptomatic treatment and monitoring of renal function. Hemodialysis may be considered in severe cases, though favipiravir’s protein binding (54–59%) may limit efficacy of this intervention.
Storage
Store in original packaging at 15–30°C. Protect from light and moisture. Keep out of reach of children. Do not use after expiration date printed on packaging. Do not transfer tablets to other containers, as this may compromise stability.
Disclaimer
This information is for educational purposes and does not replace professional medical advice. Prescription and use must be under supervision of qualified healthcare provider. Dosage and indications may vary by jurisdiction—always follow local prescribing information. Manufacturer not liable for off-label use or incorrect administration.
Reviews
“Movfor demonstrated remarkable efficacy in our influenza outbreak management, with patients showing symptom resolution 48 hours faster than standard care.” – Infectious Disease Specialist, Tokyo
“In clinical trials, favipiravir showed consistent viral load reduction across multiple influenza strains, though monitoring of uric acid levels remains advisable.” – Clinical Pharmacologist, Journal of Antimicrobial Chemotherapy
“While not first-line in all guidelines, its broad-spectrum activity makes it valuable for complicated cases where resistance is suspected.” – Hospital Formulary Committee Member